MedinCell: Participation Terms in the Combined General Meeting
08 Agosto 2022 - 12:45PM
Business Wire
Regulatory News:
The Annual General Meeting and the Extraordinary General
Meeting will be held at MedinCell's (Paris:MEDCL)
headquarters (3 rue des Frères Lumière, 34830 Jacou, France) on
Thursday, September 8, 2022 at 6:00 p.m., Paris time
All shareholders of the company are invited to attend the
meeting or to follow it live on the company’s website via the
link
https://www.medincell.com/en/investors/#meeting_
The secure remote voting system via the Votaccess platform
will be open from Thursday, August 18, 2022 at 9:00 a.m. to
Wednesday, September 7, 2022 at 3:00 p.m., Paris time
MedinCell will hold a video conference on Monday, September
5, 2022 at 6:30 p.m. to present the resolutions of the Annual
General Meeting and answer questions from shareholders.
Connection link:
https://www.medincell.com/en/investors/#meeting
An internet connection will be required to access the conference
and ask questions.
Terms and conditions of
participation
MedinCell strongly encourages all of its shareholders to
exercise their voting rights, either by remote voting, which must
be cast ahead of the General Meeting, or during the General Meeting
for shareholders physically present.
MedinCell's shareholders who wish to vote remotely may do so
before the General Meeting as follows:
- Internet voting will be available and
should be used as a priority: the secure voting platform Votaccess
will be open from Thursday, August 18, 2022 at 9:00 a.m. to
Wednesday, September 7, 2022 at 3:00 p.m., Paris time.
Shareholders will be able to vote by Internet or give their proxy
to the Chairman of the Meeting until the day before the Meeting
(i.e. Wednesday, September 7, 2022) at 3:00 p.m., Paris time.
- Shareholders may also vote by mail in
accordance with the procedures indicated in the notice of meeting,
valid as notice of convocation, published in the Bulletin des
Annonces Légales et Obligatoires on August 1st 2022. The deadline
for receipt of forms is September 5, 2022. If a proxy is given to a
natural or legal person, the proxy sends his or her voting
instructions by e-mail to the following address:
ct-mandataires-assemblees@caceis.com. The deadline for receipt is
September 7, 2022 at 3:00 p.m.
All shareholders may send their written questions, either by
registered letter with return receipt requested addressed to the
Chairman of the Executive Board at the company's registered office
(3 rue des Frères Lumière, 34830 Jacou) or by e-mail to
legal@medincell.com, no later than the second business day
preceding the date of the Shareholders' Meeting (i.e. September 6,
2022). Questions must be accompanied by a certificate of account
registration.
As the company does not have the possibility to control the
identity of the persons attending the meeting remotely, only the
persons physically present will be able to ask questions during the
General Meeting.
Availability of documents relating to
the General Meeting
The notice of meeting, valid as notice of convocation, which
includes the agenda and draft resolutions as well as the main terms
of participation and voting at the Shareholders' Meeting, was
published in the Bulletin des Annonces Légales et Obligatoires N°.
91 of August 1st 2022.
The preparatory documents and information relating to this
General Meeting will be made available to shareholders in
accordance with the legal and regulatory conditions, and will be
available on the website: www.medincell.com
Shareholders are invited to consult regularly the section
dedicated to the Meeting on the company's website:
www.medincell.com
About MedinCell
MedinCell is a pharmaceutical company at premarketing stage that
develops a portfolio of long-acting injectable products in various
therapeutic areas by combining its proprietary BEPO® technology
with active ingredients already known and marketed. Through the
controlled and extended release of the active pharmaceutical
ingredient, MedinCell makes medical treatments more efficient,
particularly thanks to improved compliance, i.e. compliance with
medical prescriptions, and to a significant reduction in the
quantity of medication required as part of a one-off or chronic
treatment. The BEPO® technology makes it possible to control and
guarantee the regular delivery of a drug at the optimal therapeutic
dose for several days, weeks or months starting from the
subcutaneous or local injection of a simple deposit of a few
millimeters, fully bioresorbable. MedinCell collaborate with tier
one pharmaceuticals companies and foundations to improve Global
Health through new therapeutic options. Based in Montpellier,
MedinCell currently employs more than 150 people representing over
30 different nationalities. www.medincell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220808005513/en/
MedinCell David Heuzé Communication leader
david.heuze@medincell.com +33 (0)6 83 25 21 86
NewCap Louis-Victor Delouvrier/Olivier Bricaud Investor
Relations medincell@newcap.eu +33 (0)1 44 71 94 94
NewCap Nicolas Merigeau Media Relations medincell@newcap.eu +33
(0)1 44 71 94 94
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024